Evotec SE stock (DE0005664809): New EVP for in silico and AI strengthens R&D focus

Evotec SE has named Rui Wang as Executive Vice President, Head of Global In Silico and AI, in a move aimed at deepening its computational drug discovery capabilities while the Germany-listed biotech stock continues to trade in Frankfurt and on Nasdaq.

Evotec SE has announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI, adding an experienced leader from the pharmaceutical industry to drive its data- and computation-heavy drug discovery strategy while its shares continue to trade on Xetra in Germany under the ticker EVT and on Nasdaq under EVO.

According to an Evotec press release published on 06/02/2026, Rui Wang joins from AstraZeneca, where she previously led AI initiatives, and will be responsible for embedding in silico and AI approaches across Evotecs global research and development as well as manufacturing operations, signaling a further push by the Hamburg-headquartered company into digital drug discovery and development workflows.Evotec IR release as of 06/02/2026

The stock traded at EUR 9.60 on 06/02/2026 on Xetra, according to Xetra data as of 06/02/2026, keeping the German listing in focus for domestic investors given the companys inclusion in Germanys Prime Standard segment.

In the United States, Evotecs American depositary shares on Nasdaq, listed under the ticker EVO, last closed at USD 3.07 on 05/29/2026, reflecting the companys dual-listing profile that offers access to both European and US capital markets, according to Nasdaq trading data.Nasdaq as of 05/29/2026

For German investors following domestic trading venues, Evotec also changes hands on platforms such as Tradegate and the Frankfurt Stock Exchange, with intraday volumes on 06/02/2026 indicating continued retail interest in the biotech stock alongside institutional flows on Xetra.FinanzNachrichten Xetra order book as of 06/02/2026

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Biotechnology and drug discovery services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Fee-for-service discovery projects, milestone and royalty-bearing partnerships with pharma and biotech companies
• Home exchange/listing venue: Xetra (EVT); secondary listing on Nasdaq (EVO)
• Trading currency: EUR on Xetra, USD on Nasdaq

Evotec SE: core business model

Evotec collaborates with pharmaceutical and biotech partners by providing integrated drug discovery and development platforms, generating revenue mainly from contracted research services complemented by success-based milestones and potential royalties from partnered pipelines.

Latest quarterly results for Evotec SE at a glance

In its most recently reported quarter, Evotec published figures for the first quarter of 2026 on 05/14/2026, reporting group revenues of EUR 220 million, up from EUR 210 million in the first quarter of 2025, according to the companys quarterly statement.Evotec Q1 2026 statement as of 05/14/2026

Adjusted EBITDA for Q1 2026 came in at EUR 30 million versus EUR 28 million a year earlier, while the company confirmed its full-year 2026 guidance ranges for revenues and adjusted EBITDA as outlined in the same presentation, maintaining its outlook for continued growth in its partnered research and development pipeline.Evotec investor presentation as of 05/14/2026

Conclusion

The decision by Evotec SE to appoint Rui Wang as Executive Vice President, Head of Global In Silico and AI, underlines the Hamburg-based companys intention to further integrate computational methods and AI-driven tools across its discovery and development platforms while maintaining its presence on both Xetra and Nasdaq.

Against the backdrop of its Q1 2026 results, which showed year-on-year growth in revenues and adjusted EBITDA and a confirmed full-year outlook, the new leadership role in in silico and AI could play an important part in shaping the next phase of the companys partnered R&D model and long-term pipeline economics.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.